Clenbuterol Therapy for Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a debilitating disease with progressive loss of muscle function and inevitable death usually in 3-5 years. There are currently two available therapies on the market which prolong life but do not adequately treat loss of muscle function or neurological function.
This invention provides a novel repurpose of the beta-2 adrenomimetic clenbuterol for use in ALS patients.
This therapy has already been used in asthma patients as a bronchodilator and has shown efficacy in other muscle conditions such as Pompe disease
- In preclinical studies it has shown efficacy as an ALS treatment with decreased mortality and increased muscular function
- A small clinical trial performed has also shown efficacy in ALS